NASDAQ:MRVI Maravai LifeSciences (MRVI) Stock Forecast, Price & News $10.07 +0.47 (+4.90%) (As of 12:51 PM ET) Add Compare Share Share Today's Range$9.55▼$10.2550-Day Range$9.14▼$12.5052-Week Range$9.09▼$26.26Volume691,512 shsAverage Volume2.15 million shsMarket Capitalization$2.53 billionP/E Ratio17.67Dividend YieldN/APrice Target$14.10 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability Maravai LifeSciences MarketRank™ ForecastAnalyst RatingHold2.44 Rating ScoreUpside/Downside38.2% Upside$14.10 Price TargetShort InterestHealthy5.72% of Float Sold ShortDividend StrengthN/ASustainability-1.23Upright™ Environmental ScoreNews Sentiment0.96Based on 5 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.06) to ($0.02) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.80 out of 5 starsMedical Sector68th out of 970 stocksPharmaceutical Preparations Industry17th out of 451 stocks 4.2 Analyst's Opinion Consensus RatingMaravai LifeSciences has received a consensus rating of Hold. The company's average rating score is 2.44, and is based on 4 buy ratings, 5 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $14.10, Maravai LifeSciences has a forecasted upside of 38.2% from its current price of $10.20.Amount of Analyst CoverageMaravai LifeSciences has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.0 Short Interest Percentage of Shares Shorted5.72% of the float of Maravai LifeSciences has been sold short.Short Interest Ratio / Days to CoverMaravai LifeSciences has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Maravai LifeSciences has recently decreased by 1.12%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldMaravai LifeSciences does not currently pay a dividend.Dividend GrowthMaravai LifeSciences does not have a long track record of dividend growth. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreMaravai LifeSciences has received a 67.24% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is driven by its "Deoxyribonucleic acid (DNA)", "Microbiology laboratory services for research", and "Clinical research services for genetic diseases" products. See details.Environmental SustainabilityThe Environmental Impact score for Maravai LifeSciences is -1.23. Previous Next 3.3 News and Social Media Coverage News SentimentMaravai LifeSciences has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.67 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Maravai LifeSciences this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for MRVI on MarketBeat in the last 30 days. This is a decrease of -83% compared to the previous 30 days.MarketBeat Follows88 people have added Maravai LifeSciences to their MarketBeat watchlist in the last 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Maravai LifeSciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.22% of the stock of Maravai LifeSciences is held by insiders.Percentage Held by Institutions50.25% of the stock of Maravai LifeSciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Maravai LifeSciences are expected to grow in the coming year, from ($0.06) to ($0.02) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Maravai LifeSciences is 17.90, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 116.57.Price to Earnings Ratio vs. SectorThe P/E ratio of Maravai LifeSciences is 17.90, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 106.05.Price to Book Value per Share RatioMaravai LifeSciences has a P/B Ratio of 2.87. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Maravai LifeSciences (NASDAQ:MRVI) StockMaravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as plasmid DNA and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, Viral Clearance Prediction kits, and custom services. It serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.Read More MRVI Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MRVI Stock News HeadlinesSeptember 29, 2023 | finance.yahoo.comMaravai LifeSciences Hosts 2023 Investor R&D DaySeptember 26, 2023 | finance.yahoo.comIs Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Expensive For A Reason? A Look At Its Intrinsic ValueSeptember 29, 2023 | PressReach (Ad)This Stock's a Sleeping GiantThe stock everyone has their eye on - discover why it's the talk of the investment world. September 24, 2023 | americanbankingnews.comMaravai LifeSciences (NASDAQ:MRVI) Trading Down 2.4%September 24, 2023 | americanbankingnews.comMaravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Receives Average Rating of "Hold" from AnalystsSeptember 21, 2023 | americanbankingnews.comInvestors Purchase Large Volume of Maravai LifeSciences Put Options (NASDAQ:MRVI)September 5, 2023 | finance.yahoo.comMaravai LifeSciences to Host 2023 Investor R&D DayAugust 29, 2023 | markets.businessinsider.comRBC Capital Sticks to Its Buy Rating for Maravai Lifesciences Holdings (MRVI)September 29, 2023 | PressReach (Ad)This Stock's a Sleeping GiantThe stock everyone has their eye on - discover why it's the talk of the investment world. August 23, 2023 | finance.yahoo.comCygnus Technologies Receives 2023 R&D 100 Award for MockV® RVLP KitAugust 22, 2023 | finance.yahoo.com11 Most Undervalued Biotech Stocks to Buy According to AnalystsAugust 9, 2023 | finance.yahoo.comMaravai LifeSciences Announces August 2023 Investor Conference ScheduleAugust 9, 2023 | finance.yahoo.comWhat Does The Future Hold For Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI)? These Analysts Have Been Cutting Their EstimatesAugust 8, 2023 | 247wallst.comKeyBanc Downgrades Maravai LifeSciencesAugust 8, 2023 | msn.comGoldman Sachs Maintains Maravai LifeSciences Holdings Inc - (MRVI) Neutral RecommendationAugust 8, 2023 | msn.comKeybanc Downgrades Maravai LifeSciences Holdings Inc - (MRVI)August 8, 2023 | msn.comMaravai LifeSciences Holdings Non-GAAP EPS of $0.00 misses by $0.01, revenue of $68.9M misses by $2.23MAugust 8, 2023 | seekingalpha.comMaravai LifeSciences Holdings, Inc. 2023 Q2 - Results - Earnings Call PresentationJuly 24, 2023 | finance.yahoo.comMaravai LifeSciences To Host Earnings Conference Call on Monday, August 7, 2023July 20, 2023 | finance.yahoo.comMaravai LifeSciences Announces Appointment of New Director to the BoardJuly 18, 2023 | finance.yahoo.comZimVie Inc. (ZIMV) Stock Jumps 20.6%: Will It Continue to Soar?July 16, 2023 | finance.yahoo.comMaravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?June 16, 2023 | seekingalpha.comMaravai LifeSciences gains amid report of latest takeover interestJune 6, 2023 | finance.yahoo.comCongressman Scott Peters Tours Maravai’s RNA manufacturing facilityMay 31, 2023 | msn.comMaravai gains amid report of $17 a share takeover bid from Thomas H. LeeMay 30, 2023 | markets.businessinsider.comStifel Nicolaus Remains a Buy on Maravai Lifesciences Holdings (MRVI)May 24, 2023 | finance.yahoo.comTriLink BioTechnologies® Announces Manufacturing Capabilities Expansion as mRNA Manufacturing Facility Nears CompletionSee More Headlines Receive MRVI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Maravai LifeSciences and its competitors with MarketBeat's FREE daily newsletter. Email Address MRVI Company Calendar Last Earnings8/07/2023Today9/29/2023Next Earnings (Estimated)11/01/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MRVI CUSIPN/A CIK1823239 Webwww.maravai.com Phone858-546-0004FaxN/AEmployees660Year FoundedN/APrice Target and Rating Average Stock Price Forecast$14.10 High Stock Price Forecast$24.00 Low Stock Price Forecast$8.00 Forecasted Upside/Downside+46.9%Consensus RatingHold Rating Score (0-4)2.44 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)$0.57 Trailing P/E Ratio16.84 Forward P/E RatioN/A P/E GrowthN/ANet Income$220.21 million Net Margins13.88% Pretax Margin35.25% Return on Equity20.67% Return on Assets8.04% Debt Debt-to-Equity Ratio0.62 Current Ratio9.33 Quick Ratio8.70 Sales & Book Value Annual Sales$883 million Price / Sales2.73 Cash Flow$2.06 per share Price / Cash Flow4.66 Book Value$3.55 per share Price / Book2.70Miscellaneous Outstanding Shares251,020,000Free Float250,466,000Market Cap$2.41 billion OptionableNot Optionable Beta-0.23 10 Best Stocks to Own in 2023Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2023 and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Carl W. Hull (Age 64)Co-Founder & Exec. Chairman Comp: $1.45MMr. William E. Martin III (Age 48)Chief Exec. Officer Comp: $2.07MMr. Kevin M. Herde (Age 51)Exec. VP & CFO Comp: $778.28kDr. Peter Michael Leddy Ph.D. (Age 60)Exec. VP & Chief Admin. Officer Comp: $757kMs. Christine Dolan (Age 55)Chief Operating Officer of Biologics Safety Testing Comp: $755.97kMs. Debra HartSr. Director of Investor RelationsMr. Kurt Oreshack (Age 42)Exec. VP, Gen. Counsel & Sec. Ms. Doreen PippenVP of MarketingMs. Becky BuzzeoChief Commercial OfficerDr. Kate E. Broderick Ph.D.Chief Innovation OfficerMore ExecutivesKey CompetitorsGalapagosNASDAQ:GLPGMirati TherapeuticsNASDAQ:MRTXNuvalentNASDAQ:NUVLGemini TherapeuticsNASDAQ:GMTXAkero TherapeuticsNASDAQ:AKROView All CompetitorsInstitutional OwnershipVirginia Retirement Systems ET ALBought 104,500 shares on 8/22/2023Ownership: 0.042%Comerica BankBought 1,436 shares on 8/22/2023Ownership: 0.001%California State Teachers Retirement SystemSold 10,905 shares on 8/21/2023Ownership: 0.054%Osaic Holdings Inc.Sold 1,374 shares on 8/21/2023Ownership: 0.001%Orion Portfolio Solutions LLCBought 22,833 shares on 8/17/2023Ownership: 0.021%View All Institutional Transactions MRVI Stock - Frequently Asked Questions Should I buy or sell Maravai LifeSciences stock right now? 9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Maravai LifeSciences in the last twelve months. There are currently 5 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" MRVI shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MRVI, but not buy additional shares or sell existing shares. View MRVI analyst ratings or view top-rated stocks. What is Maravai LifeSciences' stock price forecast for 2023? 9 analysts have issued 1 year price objectives for Maravai LifeSciences' shares. Their MRVI share price forecasts range from $8.00 to $24.00. On average, they anticipate the company's share price to reach $14.10 in the next twelve months. This suggests a possible upside of 46.9% from the stock's current price. View analysts price targets for MRVI or view top-rated stocks among Wall Street analysts. How have MRVI shares performed in 2023? Maravai LifeSciences' stock was trading at $14.31 at the beginning of 2023. Since then, MRVI stock has decreased by 32.9% and is now trading at $9.60. View the best growth stocks for 2023 here. When is Maravai LifeSciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023. View our MRVI earnings forecast. How were Maravai LifeSciences' earnings last quarter? Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) issued its quarterly earnings results on Monday, August, 7th. The company reported ($0.06) earnings per share for the quarter, missing the consensus estimate of ($0.02) by $0.04. The firm had revenue of $68.91 million for the quarter, compared to the consensus estimate of $70.30 million. Maravai LifeSciences had a net margin of 13.88% and a trailing twelve-month return on equity of 20.67%. What ETFs hold Maravai LifeSciences' stock? ETFs with the largest weight of Maravai LifeSciences (NASDAQ:MRVI) stock in their portfolio include Morningstar US Small Growth (MSGR), Janus Henderson Small Cap Growth Alpha ETF (JSML), First Trust Health Care AlphaDEX Fund (FXH) and Putnam BioRevolution ETF (SYNB).WisdomTree U.S. SmallCap Fund (EES). What guidance has Maravai LifeSciences issued on next quarter's earnings? Maravai LifeSciences issued an update on its FY 2023 earnings guidance on Monday, August, 7th. The company provided EPS guidance of $0.04-$0.08 for the period, compared to the consensus earnings per share estimate of $0.29. The company issued revenue guidance of $300.00 million-$325.00 million, compared to the consensus revenue estimate of $403.92 million. When did Maravai LifeSciences IPO? (MRVI) raised $1.3 billion in an initial public offering (IPO) on Friday, November 20th 2020. The company issued 50,000,000 shares at a price of $24.00-$27.00 per share. Morgan Stanley, Jefferies and Goldman Sachs acted as the underwriters for the IPO and BofA Securities, Credit Suisse, UBS Investment Bank, Baird, William Blair, Stifel, Keybanc Securities, Academy Securities, Loop Capital Markets, Penserra Securities and Tigress Financial Partners were co-managers. What is Maravai LifeSciences' stock symbol? Maravai LifeSciences trades on the NASDAQ under the ticker symbol "MRVI." How do I buy shares of Maravai LifeSciences? Shares of MRVI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Maravai LifeSciences' stock price today? One share of MRVI stock can currently be purchased for approximately $9.60. How much money does Maravai LifeSciences make? Maravai LifeSciences (NASDAQ:MRVI) has a market capitalization of $2.41 billion and generates $883 million in revenue each year. The company earns $220.21 million in net income (profit) each year or $0.57 on an earnings per share basis. How many employees does Maravai LifeSciences have? The company employs 660 workers across the globe. How can I contact Maravai LifeSciences? Maravai LifeSciences' mailing address is 10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO CA, 92121. The official website for the company is www.maravai.com. The company can be reached via phone at 858-546-0004 or via email at ir@maravai.com. This page (NASDAQ:MRVI) was last updated on 9/29/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Maravai LifeSciences Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.